PAR · GNFT.PA
Genfit S.A.
€11.40-€0.06 (-0.52%)
Genfit S.A.’s quoted price sits in the upper half of its reported 52-week range, 26.36% below the high.
Loading market information…
PAR · ALCLS.PA · EUR
Stock price, earnings
Quote as of Oct 29, 2026, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Cellectis S.A.’s quoted price sits in the lower half of its reported 52-week range, 76.8% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Cellectis S.A.’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -€0.16. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cellectis S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 12, 2025 |
| -€0.18+21.74% vs estimate |
| €9.70M-23.69% vs estimate |
| Q4 2024 | Mar 13, 2025 | -€0.16+10.02% vs estimate | €30.55M+234.7% vs estimate |
|---|
| Q3 2024 | Nov 5, 2024 | -€0.23+14.81% vs estimate | €14.77M-27.64% vs estimate |
|---|
THE ANALYST VIEW
16 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€11.40-€0.06 (-0.52%)
Genfit S.A.’s quoted price sits in the upper half of its reported 52-week range, 26.36% below the high.
€24.10+€0.20 (+0.84%)
LNA Santé S.A.’s quoted price sits in the lower half of its reported 52-week range, 33.97% below the high.
€0.72-€0.01 (-1.63%)
Transgene S.A.’s quoted price sits in the lower half of its reported 52-week range, 51.8% below the high.
€1.29+€0.01 (+0.63%)
Innate Pharma S.A.’s quoted price sits in the lower half of its reported 52-week range, 44.81% below the high.
€6.87+€0.61 (+9.74%)
Guerbet S.A.’s quoted price sits in the lower half of its reported 52-week range, 62.38% below the high.
€1.69+€0.02 (+1.07%)
ABIONYX Pharma S.A.’s quoted price sits in the lower half of its reported 52-week range, 63.17% below the high.
€3.06-€0.06 (-1.99%)
Adocia S.A.’s quoted price sits in the lower half of its reported 52-week range, 68.29% below the high.
€8.90+€0.10 (+1.14%)
Sensorion S.A.’s quoted price sits in the lower half of its reported 52-week range, 77.97% below the high.
